Compare SVC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVC | PRLD |
|---|---|---|
| Founded | 1995 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.6M | 325.7M |
| IPO Year | 1995 | 2020 |
| Metric | SVC | PRLD |
|---|---|---|
| Price | $1.79 | $3.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $2.50 | ★ $5.67 |
| AVG Volume (30 Days) | ★ 8.4M | 412.7K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | ★ 26.95 | 23.21 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,814,838,000.00 | $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | $1.39 | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $1.13 | $0.75 |
| 52 Week High | $3.08 | $5.54 |
| Indicator | SVC | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 59.82 | 40.52 |
| Support Level | $1.66 | $1.14 |
| Resistance Level | $1.96 | $4.10 |
| Average True Range (ATR) | 0.09 | 0.37 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 80.36 | 11.59 |
Service Properties Trust is a real estate investment trust that owns hotel properties. These properties are located in the United States, along with Canada and Puerto Rico. The company operates through its segments hotel investment unit, and net lease investments. The firm derives the majority of its revenue from the hotel real estate investments unit. The hotels are distinguished between their service levels, which include full service, select service, and extended stay; and chain scale, which includes luxury, upper upscale, upscale, upper midscale, and midscale. The hotels are extended stay or upscale. Some of the hotel brands include Courtyard by Marriott, Royal Sonesta, Crowne Plaza, Hyatt Place, and others.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.